FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response.	0.5							

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Mehra Anand (Last) (First) (Middle) C/O ACLARIS THERAPEUTICS, INC. 640 LEE ROAD, SUITE 200					3. 06	2. Issuer Name and Ticker or Trading Symbol Aclaris Therapeutics, Inc. [ACRS] 3. Date of Earliest Transaction (Month/Day/Year) 06/02/2022 4. If Amendment, Date of Original Filed (Month/Day/Year)								S. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (specify below) below) 6. Individual or Joint/Group Filing (Check Applicable)					
(Street) WAYNE (City)		tate)	19087 (Zip)	n-Dorio		If Amendment, Date of Original Filed (Month/Day/Year) tive Securities Acquired, Disposed of, or Benefice								Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
1. Title of Security (Instr. 3) 2. Trans: Date					sactio	action 2A. Deemed Execution Date,			3. Transa Code (ection	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			5. Amount of Securities Beneficially		Form: Direct	7. Nature of Indirect		
(Mon				(WOTCH)	Day/ i	Day/Year) if any (Month/Day/Year)			v	/ /// or		Price	Owned For Reported Transaction	Owned Following Reported Transaction(s) (Instr. 3 and 4)		str. 4)	Ownership (Instr. 4)		
Common Stock 06/02				3/202	3/2022		M		3,356 A		(1)	+`	34,197		D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/		ransa ode (l	5. Number of Derivative Securities		6. Date Exercisable and Expiration Date (Month/Day/Year) (Month/Day/Year) 7. Title and Am of Securities Underlying Derivative Sec (Instr. 3 and 4)			es J Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				c	ode	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)				
Stock Option (Right to Buy)	\$14.48	06/02/2022			Α		15,750		(2)(3)		06/01/2032	Common Stock	15,750	\$0.00	15,75	0	D		
Restricted Stock Units	(1)	06/02/2022			Α		4,507		(2)(4)		(4)	Common Stock	4,507	\$0.00	4,507	7	D		
Restricted Stock Units	(1)	06/03/2022			M			3,356	(5)		(5)	Common Stock	3,356	\$0.00	0		D		

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- 2. This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy.
- 3. The shares subject to this option will vest in twelve equal monthly installments commencing July 2, 2022, subject to Reporting Person's continuous service through each such date.
- 4. The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date.
- 5. The shares underlying these restricted stock units vested on June 3, 2022.

Remarks:

/s/ Mark Ballantyne, Attorneyin-Fact

06/06/2022

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.